Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + gemcitabine + pemetrexed (Guangzhou Medical University)
- Development stage
- Phase 2
- Lead developer
- Guangzhou Medical University
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This personalized chemotherapy approach, evaluated by Guangzhou Medical University, involves the biomarker-driven selection of adjuvant treatment for patients with resected non-small cell lung cancer (NSCLC). The regimen utilizes three established small molecule chemotherapy agents: carboplatin, gemcitabine, and pemetrexed. In this strategy, patients are assigned to either a carboplatin plus gemcitabine or a carboplatin plus pemetrexed doublet based on the tumor's protein expression levels of ERCC1 (excision repair cross-complementation group 1), RRM1 (ribonucleotide reductase M1), and TS (thymidylate synthase). Carboplatin acts as a DNA alkylating agent that induces cross-links, gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase, and pemetrexed is a multi-target antifolate that primarily inhibits thymidylate synthase. The goal of this individualized selection is to optimize efficacy and improve disease-free survival by matching the chemotherapy regimen to the molecular profile of the patient's tumor.
- Other names
- Personalized Therapy for Non-small Cell Lung Cancer Based on ERCC1/RRM1/TS Expression
02
Targets
DNADNA polymerase familyDHFR (Dihydrofolate reductase)RNR (Ribonucleotide reductase)TS (Thymidylate synthase)GART (GAR transformylase)
Beyond the preview
Go deeper on carboplatin + gemcitabine + pemetrexed (Guangzhou Medical University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + gemcitabine + pemetrexed (Guangzhou Medical University).